CRISPR Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "CRISPR Therapies Pipeline Insight 2023" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CRISPR pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the CRISPR Pipeline Report
• DelveInsight's CRISPR pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for CRISPR treatment.
• The leading companies working in the CRISPR Market include Intima Bioscience Inc., Masonic Cancer Center, Shanghai BDgene Co. Ltd., HuidaGene Therapeutics Co., Ltd., Caribou Biosciences Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics, EdiGene Inc., Excision Bio Therapeutics, ICON Clinical Research, MRI Global, Editas Medicine Inc., Chengdu MedGenCell Co. Ltd., Intellia Therapeutics, and others.
• Promising CRISPR Pipeline Therapies in the various stages of development include Cyclophosphamide, Fludarabine, Aldesleukin, BD111 Adult single group Dose, HG202, CB-011, VGB-Ex01, CTX001, and others.
• September 2023: Intellia Therapeutics announced a study of phase 1 clinical trials for NTLA-2001. This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM) or wild type cardiomyopathy (ATTRwt-CM)
• October 2023: Editas Medicine Inc. announced a study of phase 1 & 2 clinical trials for EDIT-301. The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia.

Request a sample and discover the recent advances in CRISPR Treatment Drugs @ CRISPR Pipeline Report- https://www.delveinsight.com/report-store/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the CRISPR pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, CRISPR NDA approvals (if any), and product development activities comprising the technology, CRISPR Therapies collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

CRISPR Overview
CRISPRs are specialized stretches of DNA. ""CRISPR"" stands for ""clusters of regularly interspaced short palindromic repeats."" It is a specialized region of DNA with two distinct characteristics: the presence of nucleotide repeats and spacers. Repeated sequences of nucleotides - the building blocks of DNA - are distributed throughout a CRISPR region.

Find out more about CRISPR Therapeutics Assessment @ CRISPR Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

CRISPR Emerging Drugs Profile
• CTX001: CRISPR Therapeutics
• EDIT-101: Editas Medicine

CRISPR Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the CRISPR Therapies. The CRISPR Therapies companies which have their CRISPR Therapies drug candidates in the most advanced stage, i.e. Phase I/II include, CRISPR therapeutics.

CRISPR Pipeline Segmentation
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Learn more about the emerging CRISPR Pipeline Therapies @ CRISPR Clinical Trials Assessment- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the CRISPR Pipeline Report
• Coverage- Global
• CRISPR Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• CRISPR Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• CRISPR Companies- Intima Bioscience Inc., Masonic Cancer Center, Shanghai BDgene Co. Ltd., HuidaGene Therapeutics Co., Ltd., Caribou Biosciences Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics, EdiGene Inc., Excision Bio Therapeutics, ICON Clinical Research, MRI Global, Editas Medicine Inc., Chengdu MedGenCell Co. Ltd., Intellia Therapeutics, and others.
• CRISPR Pipeline Therapies- Cyclophosphamide, Fludarabine, Aldesleukin, BD111 Adult single group Dose, HG202, CB-011, VGB-Ex01, CTX001, and others.

Dive deep into rich insights for new drugs for CRISPR Treatment, Visit @ CRISPR Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. CRISPR Therapies: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Early Stage Products (Phase I/II)
10. CTX001: CRISPR Therapeutics
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. LBP-EC01: Locus Biosciences
14. Drug profiles in the detailed report…..
15. Inactive Products
16. CRISPR Therapies Key Companies
17. CRISPR Therapies Key Products
18. CRISPR Therapies- Unmet Needs
19. CRISPR Therapies- Market Drivers and Barriers
20. CRISPR Therapies- Future Perspectives and Conclusion
21. CRISPR Therapies Analyst Views
22. CRISPR Therapies Key Companies
23. Appendix

For further information on the CRISPR Pipeline therapeutics, reach out to CRISPR Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/crispr-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.